401 related articles for article (PubMed ID: 11788817)
1. PET imaging in breast cancer.
Bombardieri E; Crippa F
Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
[TBL] [Abstract][Full Text] [Related]
2. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
3. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE
Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
[TBL] [Abstract][Full Text] [Related]
5. Position of nuclear medicine modalities in the diagnostic work-up of breast cancer.
Buscombe JR; Holloway B; Roche N; Bombardieri E
Q J Nucl Med Mol Imaging; 2004 Jun; 48(2):109-18. PubMed ID: 15243412
[TBL] [Abstract][Full Text] [Related]
6. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Smith IC; Ogston KN; Whitford P; Smith FW; Sharp P; Norton M; Miller ID; Ah-See AK; Heys SD; Jibril JA; Eremin O
Ann Surg; 1998 Aug; 228(2):220-7. PubMed ID: 9712568
[TBL] [Abstract][Full Text] [Related]
7. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
[TBL] [Abstract][Full Text] [Related]
8. Fluorodeoxyglucose-PET in the management of breast cancer.
Kumar R; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1113-22, ix. PubMed ID: 15488561
[TBL] [Abstract][Full Text] [Related]
9. Clinical application of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in breast cancer.
Bernsdorf M; Graff J
Clin Physiol Funct Imaging; 2014 Nov; 34(6):426-33. PubMed ID: 24267489
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
Utech CI; Young CS; Winter PF
Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
Adler LP; Crowe JP; al-Kaisi NK; Sunshine JL
Radiology; 1993 Jun; 187(3):743-50. PubMed ID: 8497624
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET/CT in the staging of local/regional metastases in breast cancer.
Robertson IJ; Hand F; Kell MR
Breast; 2011 Dec; 20(6):491-4. PubMed ID: 21807517
[TBL] [Abstract][Full Text] [Related]
13. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET.
Eubank WB; Mankoff DA; Vesselle HJ; Eary JF; Schubert EK; Dunnwald LK; Lindsley SK; Gralow JR; Austin-Seymour MM; Ellis GK; Livingston RB
Radiographics; 2002; 22(1):5-17. PubMed ID: 11796893
[TBL] [Abstract][Full Text] [Related]
14. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography.
Inoue T; Yutani K; Taguchi T; Tamaki Y; Shiba E; Noguchi S
J Cancer Res Clin Oncol; 2004 May; 130(5):273-8. PubMed ID: 14986112
[TBL] [Abstract][Full Text] [Related]
15. F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging.
Avril N; Adler LP
Radiol Clin North Am; 2007 Jul; 45(4):645-57, vi. PubMed ID: 17706529
[TBL] [Abstract][Full Text] [Related]
16. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
17. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
[TBL] [Abstract][Full Text] [Related]
18. Overview of the current status of PET in breast cancer imaging.
Wahl RL
Q J Nucl Med; 1998 Mar; 42(1):1-7. PubMed ID: 9646639
[TBL] [Abstract][Full Text] [Related]
19. Advantages and limitations of FDG PET in the follow-up of breast cancer.
Lind P; Igerc I; Beyer T; Reinprecht P; Hausegger K
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S125-34. PubMed ID: 15085295
[TBL] [Abstract][Full Text] [Related]
20. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.
Adler LP; Faulhaber PF; Schnur KC; Al-Kasi NL; Shenk RR
Radiology; 1997 May; 203(2):323-7. PubMed ID: 9114082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
